Top Abstract Purchase Related
Home
>
Node
>
Subnode

Effect of patients' gender on the course of chronic myeloid leukemia

Abdulkadyrov, K.M.; Rukavitzyn, O.A.; Bessmel'tsev, S.S.; Lomtev, A.I.

Voprosy Onkologii 43(3): 290-294

1997

ISSN/ISBN: 0507-3758
PMID: 9245084
Document Number: 475381
Chronic myeloid leukemia course was evaluated versus sex in 271 patients. Chronic stage involved more pronounced leukocytosis, thrombocytosis and splenomegaly in females, the latter showing higher susceptibility to anemia. As a result, treatment has to deal with a greater mass of tumor. A relatively longer survival time in males (44 and 42 months, respectively) suggest a higher effectiveness of therapy in such patients. When diagnosed, leukocytosis, thrombocytosis, enhanced splenomegaly and anemia should be regarded as factors of unfavorable prognosis.

Document emailed within 1 workday
Secure & encrypted payments

Meloni, G.; Russo, D.; Baccarani, M.; Testoni, N.; Martinelli, G.; Fanin, R.; Zuffa, E.; Rosti, G.; Alimena, G.; Saglio, G.; Mandelli, F.; Tura, S. 1999: A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. the Italian Co-operative Study Group on Chronic Myeloid Leukemia Haematologica 84(8): 707-715
Cannistra, S.A.; Groshek, P.; Griffin, J.D. 1989: Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia Leukemia 3(5): 328-334
Baccarani, M. 1998: SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768 Leukemia 12(7): 1168-1170
Frassoni, F.; Martinelli, G.; Saglio, G.; Sessarego, M.; Podestà, M.; Piaggio, G.; Farabegoli, P.; Zaccaria, A.; Testoni, N.; Remiddi, C. 1995: bcr/abl chimeric transcript in patients in remission after marrow transplantation for chronic myeloid leukemia: higher frequency of detection and slower clearance in patients grafted in advanced disease as compared to patients grafted in chronic phase Bone Marrow Transplantation 16(4): 595-601
Faber, E.; Jarosová, M.; Divoký, V.; Luhový, M.; Komenda, S.; Sulovská, I.; Hubácek, J.; Slezák, P.; Papajik, T.; Raida, L.; Heczko, M.; Indrák, K. 1997: Interferon-alpha in the treatment of patients with chronic myeloid leukemia Vnitrni Lekarstvi 43(1): 13-17
Shen, J.-k.; Zhang, G.-s.; Xiao, L. 2003: Analysis of cytogenetic features in the patients with chronic myeloid leukemia Hunan Yi Ke da Xue Xue Bao 28(4): 431-432
DeAngelo, D.J. 2014: Switching drugs midstream for patients with chronic myeloid leukemia Clinical Advances in Hematology and Oncology: H&o 12(7): 466-468
Tretiak, N.M.; Bondar, M.V.; Koval', A.I.; Slavchenko, I.I.; Mnyshenko, V.M.; Vakul'chuk, O.M.; Hordiienko, A.I. 1999: The use of Ukrainian laferon in the combined treatment of patients with chronic myeloid leukemia Likars'ka Sprava 5: 131-134
Bennour, A.; Ouahchi, I.; Moez, M.; Elloumi, M.; Khelif, A.; Saad, A.; Sennana, H. 2012: Comprehensive Analysis of BCR/ABL Variants in Chronic Myeloid Leukemia Patients Using Multiplex RT-PCR Clinical Laboratory 58(5-6): 433-439
Valent, A.; Zámecníková, A.; Karlic, H.; Nowotny, H.; Krizan, P. 1996: Variant forms of Philadelphia translocation in two patients with chronic myeloid leukemia Neoplasma 43(4): 239-244
Mendeleev, I.M.; Berliner, G.B.; Miasnikov, A.A.; Polezheav, I.N. 1986: Results of splenectomy with polychemotherapy in the treatment of 15 chronic myeloid leukemia patients Terapevticheskii Arkhiv 58(9): 84-88
Mahon, F.-X. 2019: When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia? Clinical Advances in Hematology and Oncology: H&o 17(2): 101-103
Petukhov, V.I.; Bondare, D.K.; Baravika, I.Ia.; Velik, L.V. 1981: Kinetic parameters of proliferating granulocytes in patients with chronic myeloid leukemia Terapevticheskii Arkhiv 53(9): 39-45
Cervantes, F.; Hernández-Boluda, J-Carlos.; Steegmann, J-Luis.; Conde, E.; Alvarez-Larrán, A.; López-Jiménez, J.; Osorio, S.; Villalón, Lía.; Camós, M.; García-Conde, J.; Odriozola, Jús. 2003: Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients Haematologica 88(10): 1117-1122
Jonte, F.; Fernández-Fuertes, F.; Cecchini, C.; Luño, E.; Ordóñez, A.; Fernández, C.; Suárez, P.; Lausín, A.; Fernández, J. 1992: Cause of death, survival, and prognostic factors in a series of 98 patients with chronic myeloid leukemia Sangre 37(5): 351-354
Larripa, I.; Ruiz, Mía.Sol.; Gutiérrez, M.; Bianchini, M. 2017: Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR Medicina 77(1): 61-72
Dou, X.L.; Wang, S.S.; Fang, J.L.; Yu, L.; Ren, X.; Huang, X.J.; Jiang, Q. 2018: Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia Zhonghua Nei Ke Za Zhi 57(9): 649-655
Filanovskaia, L.I.; Togo, A.V.; Shcherbakova, E.G.; Blinov, M.N. 1994: Thymidine kinase activity in leukocytes from patients with chronic myeloid leukemia at various periods in the disease Voprosy Meditsinskoi Khimii 40(1): 29-32
Sadovnikova, E.I.; Deriugina, E.I.; Drize, N.I.; Udalov, G.A.; Chertkov, I.L. 1989: Long-term culture of bone marrow from patients with PH'-positive chronic myeloid leukemia Gematologiia i Transfuziologiia 34(4): 35-39
Larrain, C.; Cruz, A.; Codoceo, V. 1984: Chronic myeloid leukemia treated with busulfan. Clinical characteristics, prognostic factors, effect of treatment and survival in 82 cases Revista Medica de Chile 112(9): 898-911